{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:20:52Z","timestamp":1772119252349,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T00:00:00Z","timestamp":1682985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T00:00:00Z","timestamp":1682985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Institutional Foundation of The First Affiliated Hospital of Xi\u2019an Jiaotong University","award":["2022YQPY08"],"award-info":[{"award-number":["2022YQPY08"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s00432-023-04817-9","type":"journal-article","created":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T00:01:44Z","timestamp":1682985704000},"page":"8769-8778","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nomogram for predicting axillary upstaging in clinical node-negative breast cancer patients receiving neoadjuvant chemotherapy"],"prefix":"10.1007","volume":"149","author":[{"given":"Amina","family":"Maimaitiaili","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peiling","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenzhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Ling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongjian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunjiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianguo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dahua","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhigang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinhua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peifen","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiandong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongchuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuowei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingsong","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongwei","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kejin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ailin","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianjun","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5236-7814","authenticated-orcid":false,"given":"Zhimin","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2636-7858","authenticated-orcid":false,"given":"Huimin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,2]]},"reference":[{"issue":"2","key":"4817_CR1","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s10549-018-4820-0","volume":"171","author":"Y Andersson","year":"2018","unstructured":"Andersson Y et al (2018) Long-term breast cancer survival in relation to the metastatic tumor burden in axillary lymph nodes. Breast Cancer Res Treat 171(2):359\u2013369","journal-title":"Breast Cancer Res Treat"},{"key":"4817_CR2","doi-asserted-by":"crossref","first-page":"117822342098037","DOI":"10.1177\/1178223420980377","volume":"14","author":"M Asaoka","year":"2020","unstructured":"Asaoka M et al (2020) Neoadjuvant chemotherapy for breast cancer: past, present, and future. Breast Cancer (auckl) 14:1178223420980377","journal-title":"Breast Cancer (auckl)"},{"issue":"11","key":"4817_CR3","doi-asserted-by":"publisher","first-page":"3475","DOI":"10.1245\/s10434-016-5463-1","volume":"23","author":"AV Barrio","year":"2016","unstructured":"Barrio AV et al (2016) How often is treatment effect identified in axillary nodes with a pathologic complete response after neoadjuvant chemotherapy? Ann Surg Oncol 23(11):3475\u20133480","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"4817_CR4","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1001\/jamasurg.2018.2696","volume":"153","author":"AU Barron","year":"2018","unstructured":"Barron AU et al (2018) Association of low nodal positivity rate among patients with ERBB2-positive or triple-negative breast cancer and breast pathologic complete response to neoadjuvant chemotherapy. JAMA Surg 153(12):1120\u20131126","journal-title":"JAMA Surg"},{"key":"4817_CR5","doi-asserted-by":"publisher","first-page":"1609785","DOI":"10.3389\/pore.2021.1609785","volume":"27","author":"K Bo\u00e9r","year":"2021","unstructured":"Bo\u00e9r K et al (2021) Pathologic complete response rates after neoadjuvant pertuzumab and trastuzumab with chemotherapy in early stage HER2-positive breast cancer - increasing rates of breast conserving surgery: a real-world experience. Pathol Oncol Res 27:1609785","journal-title":"Pathol Oncol Res"},{"issue":"19","key":"4817_CR6","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.2217\/fon-2020-1231","volume":"17","author":"P Chen","year":"2021","unstructured":"Chen P et al (2021) Laboratory indicators predict axillary nodal pathologic complete response after neoadjuvant therapy in breast cancer. Future Oncol 17(19):2449\u20132460","journal-title":"Future Oncol"},{"key":"4817_CR7","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.breast.2021.09.013","volume":"60","author":"F Corsi","year":"2021","unstructured":"Corsi F et al (2021) Development of a novel nomogram-based online tool to predict axillary status after neoadjuvant chemotherapy in cN+ breast cancer: a multicentre study on 1,950 patients. Breast 60:131\u2013137","journal-title":"Breast"},{"issue":"2","key":"4817_CR8","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247","journal-title":"Eur J Cancer"},{"issue":"8","key":"4817_CR9","first-page":"3512","volume":"12","author":"K Feng","year":"2022","unstructured":"Feng K et al (2022) A review of studies on omitting surgery after neoadjuvant chemotherapy in breast cancer. Am J Cancer Res 12(8):3512\u20133531","journal-title":"Am J Cancer Res"},{"issue":"3","key":"4817_CR10","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1245\/s10434-019-08154-5","volume":"27","author":"CS Fisher","year":"2020","unstructured":"Fisher CS et al (2020) The landmark series: axillary management in breast cancer. Ann Surg Oncol 27(3):724\u2013729","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"4817_CR11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11864-021-00879-4","volume":"22","author":"J Foldi","year":"2021","unstructured":"Foldi J et al (2021) Optimal management for residual disease following neoadjuvant systemic therapy. Curr Treat Options Oncol 22(9):79","journal-title":"Curr Treat Options Oncol"},{"issue":"6","key":"4817_CR12","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/j.apmr.2015.01.014","volume":"96","author":"N Gebruers","year":"2015","unstructured":"Gebruers N et al (2015) Incidence and time path of lymphedema in sentinel node negative breast cancer patients: a systematic review. Arch Phys Med Rehabil 96(6):1131\u20131139","journal-title":"Arch Phys Med Rehabil"},{"issue":"3","key":"4817_CR13","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/SLA.0000000000001863","volume":"264","author":"AE Giuliano","year":"2016","unstructured":"Giuliano AE et al (2016) Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: long-term follow-up from the american college of surgeons oncology group (Alliance) ACOSOG Z0011 randomized trial. Ann Surg 264(3):413\u2013420","journal-title":"Ann Surg"},{"issue":"8","key":"4817_CR14","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","volume":"22","author":"A Goldhirsch","year":"2011","unstructured":"Goldhirsch A et al (2011) Strategies for subtypes\u2013dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22(8):1736\u20131747","journal-title":"Ann Oncol"},{"issue":"6","key":"4817_CR15","doi-asserted-by":"publisher","first-page":"691","DOI":"10.6004\/jnccn.2022.0030","volume":"20","author":"WJ Gradishar","year":"2022","unstructured":"Gradishar WJ et al (2022) Breast cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 20(6):691\u2013722","journal-title":"J Natl Compr Canc Netw"},{"key":"4817_CR16","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/cncr.34540","volume":"129","author":"J Gu","year":"2022","unstructured":"Gu J et al (2022) Deep learning radiomics of ultrasonography for comprehensively predicting tumor and axillary lymph node status after neoadjuvant chemotherapy in breast cancer patients: a multicenter study. Cancer 129:356\u2013366","journal-title":"Cancer"},{"issue":"Suppl 16","key":"4817_CR17","doi-asserted-by":"publisher","first-page":"3819","DOI":"10.1002\/cncr.32830","volume":"126","author":"R Guo","year":"2020","unstructured":"Guo R et al (2020) A nomogram for predicting axillary pathologic complete response in hormone receptor-positive breast cancer with cytologically proven axillary lymph node metastases. Cancer 126(Suppl 16):3819\u20133829","journal-title":"Cancer"},{"issue":"2","key":"4817_CR18","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.clbc.2021.07.006","volume":"22","author":"JB Hammond","year":"2022","unstructured":"Hammond JB et al (2022) Characterizing occult nodal disease within a clinically node-negative, neoadjuvant breast cancer population. Clin Breast Cancer 22(2):186\u2013190","journal-title":"Clin Breast Cancer"},{"issue":"3","key":"4817_CR19","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s10549-018-4801-3","volume":"170","author":"W Haque","year":"2018","unstructured":"Haque W et al (2018) Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy. Breast Cancer Res Treat 170(3):559\u2013567","journal-title":"Breast Cancer Res Treat"},{"issue":"Suppl 1","key":"4817_CR20","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1016\/j.breast.2021.11.018","volume":"62","author":"EH Hersh","year":"2022","unstructured":"Hersh EH, King TA (2022) De-escalating axillary surgery in early-stage breast cancer. Breast 62(Suppl 1):S43-s49","journal-title":"Breast"},{"issue":"2","key":"4817_CR21","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s10549-018-4981-x","volume":"173","author":"HW Hwang","year":"2019","unstructured":"Hwang HW et al (2019) A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients. Breast Cancer Res Treat 173(2):255\u2013266","journal-title":"Breast Cancer Res Treat"},{"key":"4817_CR22","doi-asserted-by":"publisher","first-page":"32585","DOI":"10.1038\/srep32585","volume":"6","author":"X Jin","year":"2016","unstructured":"Jin X et al (2016) A nomogram for predicting the pathological response of axillary lymph node metastasis in breast cancer patients. Sci Rep 6:32585","journal-title":"Sci Rep"},{"issue":"1","key":"4817_CR23","doi-asserted-by":"publisher","first-page":"12141","DOI":"10.1038\/s41598-022-16538-z","volume":"12","author":"YJ Kang","year":"2022","unstructured":"Kang YJ et al (2022) A nomogram for predicting three or more axillary lymph node involvement before breast cancer surgery. Sci Rep 12(1):12141","journal-title":"Sci Rep"},{"key":"4817_CR24","doi-asserted-by":"publisher","first-page":"816297","DOI":"10.3389\/fonc.2022.816297","volume":"12","author":"X Kong","year":"2022","unstructured":"Kong X et al (2022) Advances in imaging in evaluating the efficacy of neoadjuvant chemotherapy for breast cancer. Front Oncol 12:816297","journal-title":"Front Oncol"},{"issue":"10","key":"4817_CR25","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S1470-2045(07)70278-4","volume":"8","author":"DN Krag","year":"2007","unstructured":"Krag DN et al (2007) Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol 8(10):881\u2013888","journal-title":"Lancet Oncol"},{"issue":"8","key":"4817_CR26","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.2217\/fon-2021-0668","volume":"18","author":"S Lopez-Tarruella","year":"2022","unstructured":"Lopez-Tarruella S et al (2022) How we treat HR-positive, HER2-negative early breast cancer. Future Oncol 18(8):1003\u20131022","journal-title":"Future Oncol"},{"key":"4817_CR27","doi-asserted-by":"publisher","first-page":"153303382211503","DOI":"10.1177\/15330338221150325","volume":"22","author":"Y Luo","year":"2023","unstructured":"Luo Y et al (2023) Axillary Downstaging and the impact of clinical axillary status on efficacy of neoadjuvant therapy for HER2-positive breast cancer: a network meta-analysis. Technol Cancer Res Treat 22:15330338221150324","journal-title":"Technol Cancer Res Treat"},{"issue":"11","key":"4817_CR28","doi-asserted-by":"publisher","first-page":"4515","DOI":"10.1245\/s10434-020-08650-z","volume":"27","author":"G Montagna","year":"2020","unstructured":"Montagna G et al (2020) Selecting node-positive patients for axillary downstaging with neoadjuvant chemotherapy. Ann Surg Oncol 27(11):4515\u20134522","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"4817_CR29","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1080\/14656566.2020.1746273","volume":"21","author":"F Montemurro","year":"2020","unstructured":"Montemurro F, Nuzzolese I, Ponzone R (2020) Neoadjuvant or adjuvant chemotherapy in early breast cancer? Expert Opin Pharmacother 21(9):1071\u20131082","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"4817_CR30","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1245\/s10434-021-11007-9","volume":"29","author":"AM Moorman","year":"2022","unstructured":"Moorman AM, Rutgers EJT, Kouwenhoven EA (2022) Omitting SLNB in breast cancer: is a nomogram the answer? Ann Surg Oncol 29(4):2210\u20132218","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"4817_CR31","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1001\/jamaoncol.2016.4163","volume":"3","author":"M Pilewskie","year":"2017","unstructured":"Pilewskie M, Morrow M (2017) Axillary nodal management following neoadjuvant chemotherapy: a review. JAMA Oncol 3(4):549\u2013555","journal-title":"JAMA Oncol"},{"issue":"10","key":"4817_CR32","doi-asserted-by":"publisher","first-page":"6267","DOI":"10.1245\/s10434-022-12193-w","volume":"29","author":"M Pilewskie","year":"2022","unstructured":"Pilewskie M et al (2022) How often do sentinel lymph node biopsy results affect adjuvant therapy decisions among postmenopausal women with early-stage HR(+)\/HER2(-) breast cancer in the post-RxPONDER era? Ann Surg Oncol 29(10):6267\u20136273","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"4817_CR33","doi-asserted-by":"publisher","first-page":"3698","DOI":"10.3390\/cancers12123698","volume":"12","author":"T Reimer","year":"2020","unstructured":"Reimer T et al (2020) Avoiding axillary sentinel lymph node biopsy after neoadjuvant systemic therapy in breast cancer: rationale for the prospective, multicentric EUBREAST-01 trial. Cancers (basel) 12(12):3698","journal-title":"Cancers (basel)"},{"issue":"3","key":"4817_CR34","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1097\/SLA.0000000000003126","volume":"271","author":"S Samiei","year":"2020","unstructured":"Samiei S et al (2020) Correlation between pathologic complete response in the breast and absence of axillary lymph node metastases after neoadjuvant systemic therapy. Ann Surg 271(3):574\u2013580","journal-title":"Ann Surg"},{"issue":"6","key":"4817_CR35","doi-asserted-by":"publisher","first-page":"e210891","DOI":"10.1001\/jamasurg.2021.0891","volume":"156","author":"S Samiei","year":"2021","unstructured":"Samiei S et al (2021) Axillary pathologic complete response after neoadjuvant systemic therapy by breast cancer subtype in patients with initially clinically node-positive disease: a systematic review and meta-analysis. JAMA Surg 156(6):e210891","journal-title":"JAMA Surg"},{"issue":"7","key":"4817_CR36","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1001\/jamasurg.2017.0562","volume":"152","author":"AB Tadros","year":"2017","unstructured":"Tadros AB et al (2017) Identification of patients with documented pathologic complete response in the breast after neoadjuvant chemotherapy for omission of axillary surgery. JAMA Surg 152(7):665\u2013670","journal-title":"JAMA Surg"},{"issue":"5","key":"4817_CR37","doi-asserted-by":"publisher","first-page":"e13077","DOI":"10.1111\/ecc.13077","volume":"28","author":"H Verbelen","year":"2019","unstructured":"Verbelen H et al (2019) Long-term morbidity after a negative sentinel node in breast cancer patients. Eur J Cancer Care (engl) 28(5):e13077","journal-title":"Eur J Cancer Care (engl)"},{"issue":"11","key":"4817_CR38","doi-asserted-by":"publisher","first-page":"5960","DOI":"10.1245\/s10434-021-09897-w","volume":"28","author":"A Weiss","year":"2021","unstructured":"Weiss A et al (2021) Factors associated with nodal pathologic complete response among breast cancer patients treated with neoadjuvant chemotherapy: results of CALGB 40601 (HER2+) and 40603 (triple-negative) (alliance). Ann Surg Oncol 28(11):5960\u20135971","journal-title":"Ann Surg Oncol"},{"issue":"18","key":"4817_CR39","doi-asserted-by":"publisher","first-page":"4451","DOI":"10.3390\/cancers14184451","volume":"14","author":"CC Yu","year":"2022","unstructured":"Yu CC et al (2022) Factors associated with axillary lymph node status in clinically node-negative breast cancer patients undergoing neoadjuvant chemotherapy. Cancers (Basel) 14(18):4451","journal-title":"Cancers (Basel)"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-04817-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-023-04817-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-04817-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T16:50:02Z","timestamp":1690476602000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-023-04817-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,2]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["4817"],"URL":"https:\/\/doi.org\/10.1007\/s00432-023-04817-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2689621\/v1","asserted-by":"object"}]},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,2]]},"assertion":[{"value":"14 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have declared that no competing interest existed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was performed in accordance with the Declaration of Helsinki and was approved by the Ethical Review Committee of the First Hospital of Jilin University (No. 2021-066). Since this study was retrospective and all data analysis was conducted anonymously, there was no informed consent of patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}